Regulations.gov document
Exhibit A - "Statement of Purdue Pharma L.P. Regarding FDA's Approval of Reformulated…
Supporting & Related Material · FDA-2010-P-0526 · posted Feb 3, 2011
Key facts
| Document ID | FDA-2010-P-0526-0013 |
|---|---|
| Title | Exhibit A - "Statement of Purdue Pharma L.P. Regarding FDA's Approval of Reformulated OxyCotin (Oxycodone HCI Controlled-Release) Tablets,"News and Media - [Rakoczy Molino Mazzochi Siwik LLP - Comment] |
| Document type | Supporting & Related Material |
| Subtype | C-Comment (Supporting and Related Material) |
| Agency | FDA |
| Docket | FDA-2010-P-0526 |
| Posted | Feb 3, 2011 |
| Effective date | Jan 25, 2011 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: